Optimizing visual outcomes by intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors is critical for detecting signs of choroidal neovascularization in patients with pathologic myopia or neutropenia. This evidence concerns the gene VEGFA and choroiditis.